The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.

Wullschleger, StephanTichet, MelanieCodarri-Deak, LauraUmana, PabloKlein, ChristianHanahan, Douglas2021-09-112021-09-112021-09-112021-07-0110.1158/1538-7445.AM2021-71https://infoscience.epfl.ch/handle/20.500.14299/181287WOS:000680263502022OncologyThe immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.text::conference output::conference proceedings::conference paper